



# MARKET RELEASE

23 June 2017

**Innate Immunotherapeutics Limited**

## **TRADING HALT**

The securities of Innate Immunotherapeutics Limited (the “Company”) will be placed in Trading Halt Session State at the request of the Company, pending the release of an announcement by the Company. Unless ASX decides otherwise, the securities will remain in Trading Halt Session State until the earlier of the commencement of normal trading on Tuesday, 27 June 2017 or when the announcement is released to the market.

Security Code: IIL

George Tharian

**ADVISER, LISTINGS COMPLIANCE (SYDNEY)**

For personal use only

23 June 2017

Mr. George Tharian  
Adviser, Listings Compliance (Sydney)  
Australian Securities Exchange

[George.Tharian@asx.com.au](mailto:George.Tharian@asx.com.au)

&

[tradinghaltssydney@asx.com.au](mailto:tradinghaltssydney@asx.com.au)


**REQUEST FOR TRADING HALT**

Innate Immunotherapeutics Limited (ASX Code : IIL) requests a Trading Halt in the securities of IIL effective immediately this Friday 23 June 2017.

For the purposes of Listing Rule 17.1 , IIL provides the following information:

- a) The Trading Halt is necessary as the Company has received results from its Phase 2B trial of MIS416 in patients with secondary progressive multiple sclerosis (SPMS).
- b) The Company requests its securities remain in a trading halt for two days to resume trading on Tuesday 27 June 2017.
- c) The event which the Company expects will end the trading halt will be the lodgement of an announcement regarding the results of the trial.
- d) The Company is not aware of any reason why the trading halt should not be granted.

Yours sincerely,



**Andrew J Cooke**  
Company Secretary

#### **About Innate Immunotherapeutics**

Innate Immunotherapeutics Limited is an Australian biotechnology company with an exciting technology that targets the human innate immune system. The innate immune system is the body's first line of defence against external disease causing pathogens such as bacteria and viruses, and internally caused diseases such as cancer. Disorders of the immune system can also cause or contribute to diseases such as multiple sclerosis. While the innate immune system is responsible for mounting the body's initial defence against threats, it also plays a critical role in controlling the overall immune response and many for the body's tissue protective and reparative functions.

#### **SPMS - The Significant Unmet Medical Need**

Multiple sclerosis is a chronic disabling condition where the body's immune system attacks the myelin sheath surrounding nerve fibres. The damaged myelin forms scar tissue which distorts or interrupts nerve impulses, disrupting the ability of parts of the nervous system to communicate properly. This can result in a wide range of symptoms, including loss of balance, muscle coordination, difficulty walking, slurred speech, tremors, stiffness, cognitive impairment, depression, fatigue and bladder problems.

Within 15 years of being diagnosed with the early 'relapsing-remitting' stage of MS, and despite the 12 drugs approved to treat this early stage of disease, about 60% of sufferers go on to develop a more advanced progressive form of disease - SPMS. After 20 years the number of SPMS sufferers increases to about 75%. **There are currently no approved drugs for the effective ongoing treatment of SPMS.** The Company's clinical development of MIS416 seeks to address this important unmet medical need and significant commercial opportunity.

#### **About MIS416**

The microparticle, MIS416, is a biologically derived novel immune modulator which can uniquely target both the regulatory and defensive functions of the innate immune system. MIS416 targets myeloid cells, a sub-set of innate immune cells not currently targeted by any other drugs in development for the treatment of SPMS.

Myeloid cells can play an important role inside the brain of a patient with SPMS by down regulating inflammation, helping clear myelin debris, and upregulating tissue repair processes.